Head, Laboratory of Molecular Pathology, Ludwig Institute for Cancer Research, USA
Professor, University of California San Diego, USA

Paul Mischel’s research is directed at defining the signal transduction and metabolic networks that promote tumor growth, focusing primarily on EGFR/PI3K/mTOR signaling and its biochemical consequences. The Mischel group has a particular interest in glioblastoma, tightly integrating studies in pre-clinical models with analyses of patients treated in state of the art clinical trials, with the goal of developing more effective, less toxic therapies. Recently, his group has also become particularly interested in the role of extrachromosomal DNA in cancer.

Dr. Mischel received his M.D. with honors (Alpha Omega Alpha) from Cornell University Medical College. He did residency and fellowship training in Anatomic Pathology and Neuropathology at the University of California, Los Angeles and followed his clinical training with a post-doctoral research fellowship in the laboratory of Dr. Louis Reichardt, at the Howard Hughes Medical Institute at University of California San Francisco. Dr. Mischel joined the faculty of UCLA in 1998, becoming the Lya and Harrision Latta Professor of Pathology and Laboratory. In August of 2012, Dr. Mischel was recruited to the Ludwig Institute for Cancer Research, San Diego Branch.

Dr. Mischel was elected to the American Society for Clinical Investigation (ASCI) and the American Association of Physicians, and he served as the Past-President of the American Society for Clinical Investigation (ASCI). He currently serves on editorial boards of several journals and on a number of scientific advisory boards.  

Dr. Mischel has published 161 scientific papers and he is the recipient of a number of honors, including The Farber Award for Brain Cancer Research. He has also been recognized as one of “America’s Top Doctors” for Cancer and for Pathology (Castle and Connolly and US News and World Report).